Mr. Dean Burns reports

OCUMETICS ACCELERATES TOWARD GROUP TWO FIRST-IN-HUMAN STUDY WITH MANUFACTURING LAUNCH OF OPTIMIZED ACCOMMODATING LENS

Ocumetics Technology Corp. has reached a major development milestone in its accommodating intraocular lens program with the receipt of precision manufacturing moulds and the launch of production and testing for its newly optimized accommodating intraocular lens.

The milestone represents a significant transition from early clinical validation to refined product execution as Ocumetics advances toward expanded clinical studies and regulatory submissions.

The newly optimized Ocumetics lens incorporates valuable surgical feedback, engineering refinements and patient outcome data collected during the company's group one first-in-human study. These enhancements are designed to improve lens performance, manufacturing consistency and long-term reliability.

A key advancement in the optimized lens architecture is the elimination of dependency on fluid optical media such as air, water or oil. By simplifying the lens design, Ocumetics believes it can achieve greater predictability of lens movement within the eye, improved mechanical durability and a more scalable, high-yield manufacturing process.

The Ocumetics lens is being developed to restore dynamic focusing ability by working in harmony with the eye's natural muscle movements, potentially allowing patients to achieve clear vision at multiple distances without glasses or contact lenses.

Development of the optimized lens was led by chief scientist Dr. Garth Webb in collaboration with Ocumetics's international engineering and manufacturing teams.

"I couldn't be more impressed with the speed, skill and innovation demonstrated by our scientific and engineering teams," said Dean Burns, president and chief executive officer of Ocumetics. "The data and experience gained from our group one first-in-human study have directly shaped our optimized lens design. With manufacturing now under way and a significantly simplified lens architecture, we believe we can accelerate development timelines while improving reliability and scalability."

Ocumetics has initiated initial production runs alongside comprehensive validation testing focused on optical performance, mechanical movement, durability and long-term functionality.

These activities are expected to support coming group two preclinical surgeries planned for early third quarter 2026.

The company continues to advance toward key regulatory milestones, including preparation for its planned investigational device exemption submission to the U.S. Food and Drug Administration.

About Ocumetics Technology Corp.

Ocumetics is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the first-in-human early feasibility study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed a dynamic intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses and without perceptible time lag.

We seek Safe Harbor.